The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,072,986 in first-year total cost, median $1,036,493.
Most frequent study sections
- Special Emphasis Panel[ZRG1 AARR-J (52)]2
Most frequent institutions
- LYNDRA THERAPEUTICS, INC.1
- UNIVERSITY OF CALIFORNIA, SAN DIEGO1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2017 | Development of Ultra Long-Acting Oral HIV Therapies1R01AI131416-01 | BELLINGER, ANDREW MARTIN | LYNDRA THERAPEUTICS, INC., MA | $1,323,542 | ZRG1 |
| 2017 | Development of Sustained-Release Anti-HIV Nucleoside Phosphonate Nanoparticles1R01AI131424-01 | SCHOOLEY, ROBERT TURNER | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $749,444 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.